Last reviewed · How we verify
N91115
At a glance
| Generic name | N91115 |
|---|---|
| Also known as | Cavosonstat |
| Sponsor | Nivalis Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study (PHASE2)
- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Cavosonstat Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE2)
- MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Cavosonstat (N91115) in Healthy Subjects (SNO-9) (PHASE1)
- Study of Cavosonstat (N91115) in Patients With CF Homozygous for the F508del-CFTR Mutation (PHASE2)
- MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetic Effects of N91115 in Healthy Subjects (PHASE1)
- Study of Cavosonstat (N91115) in CF Patients Who Are Heterozygous for F508del-CFTR and a Gating Mutation and Being Treated With Ivacaftor (PHASE2)
- PK Study of N91115 in Cystic Fibrosis Patients (PHASE1)
- A Drug-Drug Interaction Study of N91115 +/- Rifampin in Healthy Adult Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- N91115 CI brief — competitive landscape report
- N91115 updates RSS · CI watch RSS
- Nivalis Therapeutics, Inc. portfolio CI